eFFECTOR Therapeutics, Inc.: Nasdaq/NYSE listing notice — eFFECTOR Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

eFFECTOR Therapeutics, Inc.

Received Nasdaq letter on July 31, 2023; common stock bid price below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until January 29, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by Jan 29, 2024, may be eligible for an additional 180-day period if other listing standards are met.
Stock continues trading on Nasdaq Capital Market under symbol EFTR during the cure period.
Company will monitor bid price and consider options, including a potential reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 31, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 29, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-203837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.